STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. A Theranos whistleblower watched all three hours of “You Can See Everything,” so you don’t have to. Send news tips and boring truths about liars to [email protected] or John_Wilkerson.07 on Signal. The need-to-know this week Elevance Health holds its third-quarter earnings call on Wednesday. On Thursday, KFF will release its annual Employer Health Benefits Survey, which will provide insights on premiums, deductibles, and cost-sharing. Also Thursday, a federal court will hear arguments in Commonwealth of Massachusetts v. Oz, a lawsuit brought by 25 states and D.C. challenging the Trump administration’s implementation of new Medicaid work requirements. What’s in a name? FDA officials seem to be reviving a policy to ensure that drugs are tested on their intended patient populations. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe